secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0000914475-23-000056
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine Q2 beats with INGREZZA $440M (+26% YoY); raises 2023 sales forecast to $1.77-1.82B
--------------------------------------------------------------------------------

- Q2 total revenue $452.7M vs $378.2M YoY; GAAP EPS $0.95 vs loss of $0.18, non-GAAP EPS $1.25 vs $0.84.
- INGREZZA net product sales $440M (26% YoY); record new patient starts in Q2.
- 2023 INGREZZA guidance raised to $1.77-1.82B from prior range; reaffirms R&D and SG&A expense guidance.
- Cash, cash equivalents and marketable securities $1.32B at June 30, 2023; up from $1.29B at year-end 2022.
- PDUFA date for valbenazine in Huntington's chorea set for Aug 20, 2023; four Phase 2/3 readouts expected in Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000056/0000914475-23-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000056/nbix-20230801.htm
  HTML page:      https://secwatch.observer/filing/0000914475-23-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer